THE TECHNOLOGY

Canine parvovirus (CPV-2) causes serious illness and mortality in dogs. Puppies less than six months old are particularly susceptible. This invention describes a new variant of the virus called CPV-2b, which has become the dominant serotype of the virus found in dogs.

Patents          US 5,814,510, US 5,885,585
Issued          Sep 29, 1998, Mar 23, 1999
Inventors       Leland Carmichael & Colin Parrish
Licensee        Virbac Laboratories

THE PRODUCT

Canigen CPV2b

Canigen CPV2b is a vaccine comprised of live attenuated canine parvovirus 2b Strain CPV39 and is approved for use in puppies from the age of five weeks to induce protection against CPV serotypes 2b, 2a and 2.